We use cookies to improve site performance and enhance your user experience. If you'd like to disable cookies on this device, please see our cookie management page.
If you close this message or continue to use this site, you consent to our use of cookies on this devise in accordance with our cookie policy, unless you disable them.

Close

SHARES NEWS & ANALYSIS

Your filtered view of the latest news and analysis

  • 100-91: Silence Therapeutics to Blur Group

    11 April 2014

    In the first 10-company segment of our analysis of Aim's top 100 companies, we give our verdict on Silence, Providence, Unitech, Sinclair, Accesso,...
  • 90 to 81: Asian Citrus to CVS Holdings

    11 April 2014

    In the second 10-company segment of our analysis of Aim's top 100 companies, we give our verdict on Asian Citrus, Stanley Gibbons, FW Thorpe,...
  • High hopes for Vernalis cold drug

    01 April 2014

    RESULTS: Aim-listed drug company Vernalis is hoping to create a lucrative revenue stream from prescription cold medication - that could gain US regulatory...
  • Skyepharma turns a profit

    31 March 2014

    RESULTS: Developer of inhalation products Skyepharma (SKP) has exceeded market expectations with a profitable turn in 2013
  • Improved performance at Futura

    31 March 2014

    RESULTS: Condom developer Futura Medical (FUM) is excited to see the launch of several products over the next 12 months.
  • Horizon and Cambian catch tail wind

    28 March 2014

    The NASDAQ biotechnology index took a big hit last week. But is the spending spree on life sciences IPOs over?
  • Epistem looks to second-half launch

    26 March 2014

    RESULTS: Personal medicine and diagnositics group Epistem Holdings (EPH) is trying to recover from the loss of a major distribution partner
  • Bank profits from Allergy Therapeutics Tip Update

    24 March 2014

    Interim results from Allergy Therapeutics (AGY) reveal strong trading amid the rapid rise in the share price.

Register today and get...

Register today and get...
Please note terms & conditions apply